Search results
Results from the WOW.Com Content Network
cBio Cancer Genomics Portal →: Memorial Sloan-Kettering Cancer Center, United States Copy number, Mutation, Methylation, Gene Expression, miRNA Expression, Protein, Phosphorylation: No Yes Human: No Yes No International Cancer Genome Consortium →: Worldwide: Mutation: Yes Yes Human: No Yes Yes Integrative Oncogenomics Cancer Browser ...
Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer. [17] In December 2016, the Food and Drug Administration granted an accelerated approval for the use of rucaparib "for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies". [18]
The Network of Cancer Genes (NCG) is a freely accessible web resource of genes that, when altered in their sequence, drive clonal expansion of normal tissues (healthy drivers) or cancer (cancer drivers). The project was launched in 2010 and has reached its 7th release in 2022.
Colorectal cancer: 13.9 Liver cancer and bile duct cancer: 6.6 Gallbladder cancer: 0.6 Pancreatic cancer: 11.0 Laryngeal cancer: 1.0 Lung cancer: 40.2 Tracheal cancer (including other respiratory organs) 0.1 Bone cancer (including joint cancer) 0.5 Skin cancer (excluding basal and squamous) 3.4 Breast cancer (non-in situ) 11.3 Uterine cancer ...
Testicular cancer: Fulton County, New York: 3 Dimethylformamide (DMF) 2-Ethoxyethanol 2-Ethoxyethyl acetate 2-Butoxyethanol [14] 1987–1999 Brain cancer, Leukemia, Lymphoma: Wilmington, Massachusetts: 20 Unknown N-Nitrosodimethylamine (NDMA) [15] [16] [17] 1993–2008 Childhood brain cancer, brain tumors, colon cancer, anal cancer, rectal ...
MediSave, introduced in 1984, is a national medical savings account system in Singapore.By law, all working Singaporeans and permanent residents must contribute 8-10.5% of their income to their MediSave account (MSA) to cover medical expenses for themselves or approved dependents, including hospitalization, day surgery, selected outpatient treatments, and healthcare needs in later years.
MediShield Life also does not cover treatment of congenital anomalies (medical conditions that are present at birth), cosmetic surgery, pregnancy-related charges and mental illness. [ 51 ] As the MediShield Life benefits are capped for B2 or C ward hospitalization in public hospitals, Integrated Shield plans provide coverage for the ...
IARC group 2B substances, mixtures and exposure circumstances are those that have been classified as "possibly carcinogenic to humans" by the International Agency for Research on Cancer (IARC) as [1] This category is used when there is limited evidence of carcinogenicity in humans and less than sufficient evidence of carcinogenicity in experimental animals.